Navigation Links
NARSAD Introduces 'Healthy Minds Across America,' an International Event Recognizing the Toll of Mental Illness, on Sunday, Sept. 14
Date:8/26/2008

Featuring 48 Free Public Forums across U.S. and Canada on Progress and

Promise of Mental Health Research

GREAT NECK, N.Y., Aug. 26 /PRNewswire/ -- People concerned about the toll that mental health disorders are taking on their families and communities will have a unique opportunity to hear from world-class experts on what is known to-date about the causes, symptoms and progression of such illnesses as depression, bipolar disorder, anxiety, schizophrenia and autism, and learn about current and potential treatments.

In an unprecedented event called Healthy Minds Across America, 48 free public forums will take place around the United States and in Canada -- all on Sunday, September 14 -- at which some of the greatest minds and talents in neuropsychiatric research will report on the state of mental health research and how breakthroughs over the last 20 years have led to progress and hope, while uncovering new challenges.

NARSAD, the world's leading charity dedicated to mental health research, has organized Healthy Minds Across America, which is being held in partnership with many of North America's most prominent universities and research centers -- from multiple branches of the University of California and University of Texas to Yale, Harvard, the University of Pittsburgh, Duke and the University of Toronto, among dozens more.

"Never, to my knowledge, has there been such a concerted effort to bring the public together with the experts who hold the most knowledge about an area of human illness that accounts for more loss and devastation than any other," said Herbert Pardes, M.D., president of NARSAD's Scientific Council, who is also president and CEO of New York-Presbyterian Hospital and a former head of the National Institute of Mental Health. "Mental illness is so prevalent in our society, estimated to affect as many as one in four North Americans in any given year, with one in 10 suffering serious, chronic con
'/>"/>

SOURCE NARSAD
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. NARSAD researchers identify specific genes and family traits linked to mental illnesses
2. Ezra Susser, MD, DrPH, receives Distinguished Investigator Award from NARSAD
3. NARSADs 5th Annual Mission Possible Symposium Offers Insight to PTSD and Other Mental Illnesses
4. NARSAD - the Worlds Leading Mental Health Research Charity - Presents 2007 Prizes for Outstanding Psychiatric Research at New York Gala, October 19th
5. NARSAD - Worlds Leading Mental Health Research Charity - Presents 19th Annual New York Mental Health Symposium, Oct. 19th & 20th
6. CytoViva(R) Introduces Breakthrough Nano-Technology Research Tool
7. ORSupply.com Introduces New Line of Products from Flexicare
8. STEMCELL Technologies Introduces AggreWell™400 for Standardized Embryonic Stem Cell and Induced Pluripotent Stem Cell Research
9. Gerbig Engineering Introduces New Product Feature
10. Resolution Health Introduces Womens Health and Wellness Action Campaign
11. JUVA Skin & Laser Center Introduces Affirm CO2 to New York City Laser Resurfacing Clients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... 30, 2015 “ Milli the Snail ” ... which takes a look at the latest and coolest applications ... the host of AppWatch and technology expert, conducted the app ... game that engages and educates children. , Interactive mobile games ... all the content and games they are playing are doing ...
(Date:5/29/2015)... “In the current environment of opiate ... we provide education that will help practitioners address ... from pain, within the boundaries of the guidelines ... rehabilitation medicine and President/Medical Director of the International ... A new flight of PAINWeekEnd Regional Conferences offers ...
(Date:5/29/2015)... M3 USA MDLinx.com, source of the “ ... now offers The Smartest Rheumatologist . The Smartest ... ranging from Fibromyalgia and Osteoporosis, to Arthritis and Gout. ... and Caroline Tredway, editorial head of The Smartest Doc ... on the physicians who participate. Says Tredway, “With so ...
(Date:5/29/2015)... The science of Follicular Unit Extraction (FUE) ... efficient methods of FUE hair transplantation have increased the amount ... most cutting edge hair transplant methods being used to great ... extracting hair from the beard to the scalp. , Most ... male pattern baldness. Beard hair has a life cycle, ...
(Date:5/29/2015)... Jan Wooden Howse lost her husband and her ... else: God does no wrong. , It’s fitting, then, that ... is titled “God Does No Wrong.” It focuses on what ... tragedy. , “My story has a positive message about ... something productive, something healing,” Howse said. , “God Does No ...
Breaking Medicine News(10 mins):Health News:An Aesthetic Game that Engages and Educates Children was Featured on NewsWatch Television 2Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:MDLinx Launches Smartest Rheumatologist 2Health News:Beard to Scalp Hair Transplant: Newest Advance in Hair Transplant Technology 2Health News:Turning grief from a child’s passing into virtue 2
... THRM ), a leader in non-invasive tissue ... will present at the 2008 Maxim Group,Growth Conference. ... Time on Tuesday, October 7, 2008. Stephen J. ... the company,s business,strategy and historical financial results., ...
... Share Exchange Offer to the Holders of the Following Securities, ... JNJ, The K&N Value Select Corporation offers the holders of ... change into 1 share of,K&N Value Select Corp. - ISIN: CH0006603085 ... October 2008 and ends on 27th November,2008., K&N Value Select ...
... pleased to recognize the Association for Healthcare Resource and Materials ... 5-11. This week is dedicated to acknowledging and celebrating ... healthcare and the overall success of the healthcare supply chain. ... ...
... System To Reduce Claim Fraud and Costs by ... ILOG(R) (Nasdaq:,ILOG, Euronext: ILO, ISIN: FR0004042364) today announced ... in Argentina, is using ILOG,JRules(R) to automate its ... Swiss Medical has been able to reduce,unnecessary medical ...
... often seasonal allergy that affects between 10 and 20 ... a course of patient-adjusted dosing, according to new research ... Head and Neck Surgery. , During the ... allergic rhinitis, was observed in 69 patients, who were ...
... than 1 million children, Stores raise funds for Vitamin ... Quarters found in the,bottom of purses, pockets, and even on ... needy children. The Vitamin Shoppe is asking,everyone to donate their ... a,child., Affecting up to 140 million children every year, ...
Cached Medicine News:Health News:Broadlane Recognizes AHRMM National Healthcare Resource and Materials Management Week 2Health News:Broadlane Recognizes AHRMM National Healthcare Resource and Materials Management Week 3Health News:Swiss Medical Group Selects ILog JRules to Streamline Claims Processing 2Health News:Swiss Medical Group Selects ILog JRules to Streamline Claims Processing 3Health News:Hay fever may be best treated with self-adjusted dosing 2Health News:Spare Change Can Help Save the Life of a Child 2Health News:Spare Change Can Help Save the Life of a Child 3
(Date:5/29/2015)... May 29, 2015 Educating the community ... Association for the Advancement of Wound Care (AAWC), ... support from AAWC,s corporate partners, the Association provides ... on the AAWC website at http://aawconline.org/education-for-the-generalist/ . ... pathway with links to various CME/CEU educational programs. ...
(Date:5/28/2015)... May 28, 2015 ... the addition of Jain PharmaBiotech,s new report  ...  to their offering.       (Logo: ... gene silencing involves the use of double ... this material is processed into short 21-23 ...
(Date:5/28/2015)... , May 28, 2015 The controversy ... )  in hysterectomies and myomectomies (procedures to remove uterine ... the FBI is investigating Johnson & Johnson,s Ethicon, ... of the devices. According to the report published ... th , the FBI is trying to determine ...
Breaking Medicine Technology:The Association for the Advancement of Wound Care Educates the Public 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 2Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 3
... VIRGINIA BEACH, Va., July 8, 2011 The Amerigroup ... check to the Rx Partnership to benefit the Rockbridge ... is an organization that works to provide uninsured Virginians ... as a broker to access and distribute free bulk ...
... Novartis Pharmaceuticals Corporation ("Novartis") announced today Phase III ... patients taking Afinitor® (everolimus) tablets* experienced a 50% ... subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors ... the largest prospective clinical trial to date in ...
Cached Medicine Technology:Amerigroup Foundation Presents Grant to Rx Partnership 2Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 2Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 3Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 4Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 5Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 6Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 7Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 8Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 9Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 10Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 11Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 12Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 13
The °CureWrap is one-piece garment offers maximum available surface coverage, while avoiding the sterilized fields of operation....
... Antibody (IgG) Test is a semiquantitative enzyme ... significant IgG antibodies to M. pneumoniae between ... test should not be used for specimens ... (IgM) Test and is not intended for ...
... Test is a qualitative enzyme immunoassay ... Epstein-Barr virus capsid antigen (EBV-VCA), Epstein-Barr ... and Toxoplasma. When used in conjunction ... aid in the serodiagnosis of infectious ...
... Test is an enzyme immunoassay ... the presence of antibodies to ... and herpes simplex virus in ... to indicate previous or current ...
Medicine Products: